200 related articles for article (PubMed ID: 10363974)
21. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
Chu XJ; DePinto W; Bartkovitz D; So SS; Vu BT; Packman K; Lukacs C; Ding Q; Jiang N; Wang K; Goelzer P; Yin X; Smith MA; Higgins BX; Chen Y; Xiang Q; Moliterni J; Kaplan G; Graves B; Lovey A; Fotouhi N
J Med Chem; 2006 Nov; 49(22):6549-60. PubMed ID: 17064073
[TBL] [Abstract][Full Text] [Related]
22. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.
Leost M; Schultz C; Link A; Wu YZ; Biernat J; Mandelkow EM; Bibb JA; Snyder GL; Greengard P; Zaharevitz DW; Gussio R; Senderowicz AM; Sausville EA; Kunick C; Meijer L
Eur J Biochem; 2000 Oct; 267(19):5983-94. PubMed ID: 10998059
[TBL] [Abstract][Full Text] [Related]
23. Structure-activity relationship studies of flavopiridol analogues.
Murthi KK; Dubay M; McClure C; Brizuela L; Boisclair MD; Worland PJ; Mansuri MM; Pal K
Bioorg Med Chem Lett; 2000 May; 10(10):1037-41. PubMed ID: 10843211
[TBL] [Abstract][Full Text] [Related]
24. Designing inhibitors of cyclin-dependent kinases.
Hardcastle IR; Golding BT; Griffin RJ
Annu Rev Pharmacol Toxicol; 2002; 42():325-48. PubMed ID: 11807175
[TBL] [Abstract][Full Text] [Related]
25. Evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5, and GSK-3 inhibition by paullones.
Kunick C; Lauenroth K; Wieking K; Xie X; Schultz C; Gussio R; Zaharevitz D; Leost M; Meijer L; Weber A; Jørgensen FS; Lemcke T
J Med Chem; 2004 Jan; 47(1):22-36. PubMed ID: 14695817
[TBL] [Abstract][Full Text] [Related]
26. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.
De Azevedo WF; Mueller-Dieckmann HJ; Schulze-Gahmen U; Worland PJ; Sausville E; Kim SH
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2735-40. PubMed ID: 8610110
[TBL] [Abstract][Full Text] [Related]
27. SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2.
Moshinsky DJ; Bellamacina CR; Boisvert DC; Huang P; Hui T; Jancarik J; Kim SH; Rice AG
Biochem Biophys Res Commun; 2003 Oct; 310(3):1026-31. PubMed ID: 14550307
[TBL] [Abstract][Full Text] [Related]
28. Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases.
Caridha D; Kathcart AK; Jirage D; Waters NC
Bioorg Med Chem Lett; 2010 Jul; 20(13):3863-7. PubMed ID: 20627564
[TBL] [Abstract][Full Text] [Related]
29. Molecular dynamic behavior and binding affinity of flavonoid analogues to the cyclin dependent kinase 6/cyclin D complex.
Khuntawee W; Rungrotmongkol T; Hannongbua S
J Chem Inf Model; 2012 Jan; 52(1):76-83. PubMed ID: 22172011
[TBL] [Abstract][Full Text] [Related]
30. Cyclin-dependent kinase inhibitors for treating cancer.
Toogood PL
Med Res Rev; 2001 Nov; 21(6):487-98. PubMed ID: 11607930
[TBL] [Abstract][Full Text] [Related]
31. Binding of the potential antitumour agent indirubin-5-sulphonate at the inhibitor site of rabbit muscle glycogen phosphorylase b. Comparison with ligand binding to pCDK2-cyclin A complex.
Kosmopoulou MN; Leonidas DD; Chrysina ED; Bischler N; Eisenbrand G; Sakarellos CE; Pauptit R; Oikonomakos NG
Eur J Biochem; 2004 Jun; 271(11):2280-90. PubMed ID: 15153119
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of CDKs as a therapeutic modality.
Sausville EA; Johnson J; Alley M; Zaharevitz D; Senderowicz AM
Ann N Y Acad Sci; 2000 Jun; 910():207-21; discussion 221-2. PubMed ID: 10911915
[TBL] [Abstract][Full Text] [Related]
33. A new series of potent oxindole inhibitors of CDK2.
Luk KC; Simcox ME; Schutt A; Rowan K; Thompson T; Chen Y; Kammlott U; DePinto W; Dunten P; Dermatakis A
Bioorg Med Chem Lett; 2004 Feb; 14(4):913-7. PubMed ID: 15012993
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of cdk1 by alsterpaullone and thioflavopiridol correlates with increased transit time from mid G2 through prophase.
Soni DV; Jacobberger JW
Cell Cycle; 2004 Mar; 3(3):349-57. PubMed ID: 14726692
[TBL] [Abstract][Full Text] [Related]
35. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
Senderowicz AM
Invest New Drugs; 1999; 17(3):313-20. PubMed ID: 10665481
[TBL] [Abstract][Full Text] [Related]
36. Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics.
Schoepfer J; Fretz H; Chaudhuri B; Muller L; Seeber E; Meijer L; Lozach O; Vangrevelinghe E; Furet P
J Med Chem; 2002 Apr; 45(9):1741-7. PubMed ID: 11960485
[TBL] [Abstract][Full Text] [Related]
37. Cell cycle molecular targets in novel anticancer drug discovery.
Buolamwini JK
Curr Pharm Des; 2000 Mar; 6(4):379-92. PubMed ID: 10788588
[TBL] [Abstract][Full Text] [Related]
38. Molecular models of cyclin-dependent kinase 1 complexed with inhibitors.
Canduri F; Uchoa HB; de Azevedo WF
Biochem Biophys Res Commun; 2004 Nov; 324(2):661-6. PubMed ID: 15474478
[TBL] [Abstract][Full Text] [Related]
39. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
Squires MS; Feltell RE; Wallis NG; Lewis EJ; Smith DM; Cross DM; Lyons JF; Thompson NT
Mol Cancer Ther; 2009 Feb; 8(2):324-32. PubMed ID: 19174555
[TBL] [Abstract][Full Text] [Related]
40. Early development of cyclin dependent kinase modulators.
Roy KK; Sausville EA
Curr Pharm Des; 2001 Nov; 7(16):1669-87. PubMed ID: 11562305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
